cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cyteir Therapeutics Inc
2 own
2 watching
Current Price
$3.05
$0.02
(0.66%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
110.61M
52-Week High
52-Week High
3.10000
52-Week Low
52-Week Low
1.13000
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
0.00672043
P/E Ratio
P/E Ratio
41.48876292
iconMarket Capitalization110.61M
icon52-Week High3.10000
icon52-Week Low1.13000
iconAverage Volume0.03M
iconDividend Yield0.00672043
iconP/E Ratio41.48876292
What does the Cyteir Therapeutics Inc do?
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Read More
How much money does Cyteir Therapeutics Inc make?
News & Events about Cyteir Therapeutics Inc.
Business Wire
5 months ago
Cyteir Therapeutics, Inc. (Cyteir or the Company) (Nasdaq: CYT) today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor, and...
Business Wire
1 year ago
Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today presented results from a Phase 1 dose escalation monotherapy trial with CYT-0851 in a poster titled Phase 1 Results of CYT-0851 in...
Business Wire
1 year ago
Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Markus Renschler, MD, President and Chief Executive Officer will participate in a presentation at the 2022 Jefferies...
Business Wire
1 year ago
Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Krisztina Nemenyi, PhD, RAC, to its leadership team as Senior Vice President of Regulatory Affairs...
Business Wire
1 year ago
Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced today that Adam Veness, Esq. has joined Cyteir as General Counsel effective today. In this role, Mr. Veness will be part of...
Frequently Asked Questions
Frequently Asked Questions
What is Cyteir Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Cyteir Therapeutics Inc shares?
plus_minus_icon
How can I buy Cyteir Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Cyteir Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cyteir Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Cyteir Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Cyteir Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cyteir Therapeutics Inc?
plus_minus_icon
What percentage is Cyteir Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cyteir Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$3.05
$0.02
(0.66%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$0.53
$0.03 (6.76 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$1.73
$0.18 (11.61 %)
CEL-SCI Corp
CEL-SCI Corp
$2.06
$-0.19 (-8.44 %)
Codexis, Inc.
Codexis, Inc.
$2.48
$0.12 (5.08 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$0.53
$0.03 (6.76 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$1.73
$0.18 (11.61 %)
CEL-SCI Corp
CEL-SCI Corp
$2.06
$-0.19 (-8.44 %)
Codexis, Inc.
Codexis, Inc.
$2.48
$0.12 (5.08 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00